Semaglutide Weight Loss Results: What 6 Months Really Looks Like (Week-by-Week Timeline)

By Dr. Karron Power, Medical Director, PowerMD, Greenbrae, CA

Most people starting Semaglutide go looking for the same thing: real expectations. Not a celebrity before-and-after. Not a pharmaceutical company’s best-case scenario pulled from a highly controlled trial. A genuine, honest account of what actually happens to a patient’s body across 24 weeks on this medication, written by someone who has supervised patients through it.

This is that account.

The data referenced here comes from the STEP clinical trial program published in the New England Journal of Medicine, the SELECT trial published in Nature Medicine, and real-world clinical experience from managing weight loss patients at PowerMD in Greenbrae. The timeline is organized week by week through the first month, then month by month through month six, because that is how results actually accumulate: slowly at first, then meaningfully, then with the kind of momentum patients did not expect to feel.

One thing before the timeline begins: Semaglutide works on a dose-escalation schedule. You start at 0.25 mg weekly, not the full therapeutic dose. The escalation exists to minimize gastrointestinal side effects and allow the body to adjust. This means you are working toward your effective dose for the first several weeks, which is the single most important context for understanding why early results look the way they do.

How Semaglutide Works for Weight Loss

Semaglutide is a GLP-1 receptor agonist, meaning it mimics the action of glucagon-like peptide-1, a hormone your gut releases naturally after eating. GLP-1 signals the brain that you have eaten, slows the rate at which the stomach empties, and reduces appetite in the hypothalamus.

Semaglutide mimics this signal at a pharmacological level, which produces three effects relevant to weight loss:

• Appetite suppression: The “background noise” of food preoccupation that most patients with obesity or excess weight experience significantly reduces. Many patients describe this as the most noticeable early change — food becomes less interesting rather than forbidden.
• Gastric slowing: Food moves through the stomach more slowly, meaning the sensation of fullness lasts longer and overall caloric intake decreases without effort-based restriction.
• Insulin sensitivity improvement: Semaglutide improves how the body processes glucose, which has downstream effects on how the body stores and mobilizes fat, particularly visceral abdominal fat.

These mechanisms work together to produce a caloric deficit that most patients could not sustain through willpower alone, which is the core of why Semaglutide outperforms behavioral interventions in clinical trials.

Weeks 1 to 4: The Early Phase: Appetite Before Weight

Starting dose: 0.25 mg weekly

The first thing most patients notice on Semaglutide is not weight loss. It is appetite.

Within the first one to two weeks, many patients report that the constant background pull toward food has quieted. They sit down at a meal, eat less than they normally would, and feel satisfied earlier. They stop thinking about their next meal while eating the current one. For patients who have struggled with appetite regulation for years, this shift can feel remarkable before the scale has moved at all.

Visible weight loss in weeks one through four is modest for most patients. The medication is at its lowest dose and the body is adjusting. Patients typically lose two to four pounds during this period, and some see the scale move very little. This is expected and is not a sign the medication is not working.

Side effects are most common in this phase. Nausea, mild gastrointestinal discomfort, and reduced appetite can be uncomfortable at first. These typically resolve within two to four weeks as the body adjusts. Eating smaller, lower-fat meals and staying well-hydrated supports tolerance during this period.

The weight loss goal for weeks one through four is not scale movement. It is building the behavioral foundation — learning the new portion sizes, identifying which foods trigger gastrointestinal discomfort, and establishing the caloric deficit that will drive the next several months.

Month 2: When Does Real Loss Begin?

Dose escalation to 0.5 mg at week 5

Month two is when most patients begin to see consistent, meaningful weekly loss. The dose has increased, appetite suppression is established, and the behavioral changes from month one start to compound.

Clinical data from the STEP 1 trial published in the New England Journal of Medicine showed a mean weight loss of approximately 5 to 6 percent of total body weight by week 12, which sits at the end of month three. Working backward, month two represents the point at which that trajectory becomes clearly visible.

For a 200-pound patient, month two typically looks like:

• Weekly loss of one to two pounds when adherent to a reduced-calorie eating pattern
• Total loss of four to eight pounds from starting weight
• Noticeable reduction in appetite, with smaller portions feeling satisfying
• Possible reduction in cravings for highly processed or high-sugar foods

Side effects typically diminish significantly in month two for patients who tolerated month one. Nausea, the most common early complaint, resolves for most patients as the body adapts to the medication.

The key behavioral shift that supports month two results is eating in response to the medication’s satiety signals rather than previous habitual portions. Patients who continue eating the same volume as before Semaglutide do not see the same results as patients who allow the medication’s appetite reduction to guide their intake.

Months 3 to 4: The Acceleration Phase

Dose escalation continues toward 1.0 mg and potentially higher

This is the phase that most patients describe as when Semaglutide felt most transformative. The dose is approaching or at the standard therapeutic range, appetite suppression is consistent, and weight loss has accumulated to a level where patients are seeing meaningful body composition changes.

By the end of month three, average patients in clinical trials had lost approximately 5 to 8 percent of starting body weight. By the end of month four, many patients are at 8 to 12 percent. For a 200-pound starting weight, this represents 16 to 24 pounds lost.

The changes that accompany this level of loss are broader than the scale:

• Clothing fit changes noticeably
• Energy levels improve as the metabolic load of carrying excess weight reduces
• Blood pressure, fasting glucose, and cholesterol often begin improving
• Patients often report that food preoccupation has reduced substantially compared to before treatment

Visceral abdominal fat, the fat stored around internal organs that carries the highest metabolic risk, is disproportionately reduced by Semaglutide. The SELECT trial published in Nature Medicine showed a 7.7 cm reduction in waist circumference alongside a 10.2 percent mean weight reduction over the long term, which reflects this preferential visceral fat loss.

The risk of a temporary slowdown also begins in this phase for some patients. Weekly loss may reduce to under a pound as the body adjusts its basal metabolic rate in response to the lower caloric intake. This is physiologically normal and does not indicate treatment failure. Staying consistent with the medication, maintaining adequate protein intake, and incorporating strength training if possible all support continued loss through this phase.

Months 5 to 6: Plateau and How to Navigate It

The word “plateau” concerns patients who encounter it on Semaglutide, but understanding what it actually represents changes how it feels.

A plateau at months five through six typically means the rate of weekly loss has slowed significantly, not that loss has stopped entirely. Clinical trial data shows continued weight loss through the full 68-week STEP trial period, with the rate decelerating as patients approach a new, lower body weight set point.

What drives the plateau and how to manage it:

Dose ceiling. Some patients reach the maximum dose (2.4 mg weekly for Wegovy / weight management Semaglutide) and find that rate of loss slows. This is when the behavioral foundations built in months one through three become critical. The medication creates the conditions for a caloric deficit; consistent food choices and movement maintain and extend it.

Metabolic adaptation. The body’s resting metabolic rate decreases as total body weight decreases, meaning the same caloric deficit produces progressively smaller weekly losses over time. This is not a malfunction — it is basic physiology.

What helps: Reassessing dietary composition (prioritizing protein at 1.2 to 1.6 grams per kilogram of body weight), adding or increasing resistance training to preserve lean muscle mass, and maintaining the medication consistently. For some patients, a consultation to assess whether dose adjustment is appropriate is warranted.

For patients who have reached their goal or want to transition to maintenance, months five and six are also when Dr. Power begins discussing long-term plans at PowerMD, including how to sustain results if the medication is eventually discontinued.

Average Weight Loss Milestones at 6 Months

Based on the STEP trial data and real-world clinical experience:

Timepoint	Average % Body Weight Lost	For a 200 lb Starting Weight
Week 4	1 to 3%	2 to 6 lbs
Week 8	3 to 5%	6 to 10 lbs
Month 3	5 to 8%	10 to 16 lbs
Month 4	8 to 12%	16 to 24 lbs
Month 6	10 to 15%	20 to 30 lbs

These are averages from large-scale trials. Individual results vary based on starting dose, dose escalation schedule, adherence, dietary habits, baseline metabolic health, and whether the program is supervised with regular clinical oversight.

Factors That Affect Your Individual Results

No two patients follow the exact same trajectory. Variables that meaningfully affect your timeline include:

• Starting weight and metabolic history: Higher starting weights often see larger absolute losses but may have similar or slower percentage losses if metabolic factors like insulin resistance are significant
• Dose adherence and escalation speed: Patients who skip doses or who escalate too slowly spend longer at sub-therapeutic doses, which directly affects results
• Dietary protein intake: Adequate protein (at minimum 100 grams daily) supports preservation of lean muscle mass during weight loss, which protects basal metabolic rate and prevents the muscle loss that slows results
• Exercise: Strength training, even at moderate frequency, significantly improves body composition outcomes alongside Semaglutide by preserving or building lean mass as fat mass reduces
• Concurrent conditions: Hypothyroidism, polycystic ovary syndrome, insulin resistance, and certain medications can affect both the rate and the ceiling of weight loss achievable on Semaglutide
• Physician supervision: Patients in physician-supervised programs with regular check-ins, lab monitoring, and dose optimization consistently achieve better outcomes than those self-administering without clinical oversight

What Happens After You Stop Semaglutide?

This is the question patients most often do not ask until they are already thinking about stopping.

The honest answer, supported by clinical trial data: most patients who discontinue Semaglutide without a transition plan regain a significant portion of their lost weight. The STEP extension data and real-world studies show that patients who stopped Semaglutide regained approximately two-thirds of their lost weight within one year of discontinuation.

This does not mean Semaglutide is a medication that must be taken forever. It means the cessation plan matters as much as the starting plan.

At PowerMD, stopping Semaglutide is treated as a clinical transition, not an endpoint. Options discussed with patients who are approaching their goal weight or considering discontinuation include:

• Gradual dose tapering to maintain appetite regulation at a lower maintenance dose
• Transition to complementary metabolic support including Metformin for patients with insulin resistance or elevated fasting glucose
• Body composition support with truSculpt iD to address any remaining localized fat deposits that persist after overall weight reduction
• Sustained lifestyle programming and ongoing check-ins to support the behavioral habits that Semaglutide helped establish

Semaglutide at PowerMD: Physician-Supervised Medical Weight Loss

PowerMD’s medical weight loss program with Semaglutide in Greenbrae is physician-supervised from initial evaluation through ongoing treatment and any eventual transition plan. Dr. Karron Power reviews your complete health history, orders baseline labs, and designs a dosing protocol appropriate for your metabolic profile before the first injection.

Regular follow-up appointments track your progress, assess your response to dose escalation, and adjust the program based on how your body is responding. Lab monitoring includes metabolic panels, thyroid function, and relevant markers that affect weight loss trajectory. This is meaningfully different from telehealth prescription services that deliver medication without ongoing clinical relationship.

Patients from across Marin County visit PowerMD for medical weight loss including from Larkspur, Corte Madera, San Rafael, Novato, Mill Valley, Tiburon, and San Francisco. If you have been searching for “medical weight loss Marin County,” “Semaglutide Greenbrae,” or “Semaglutide Larkspur,” PowerMD is the physician-supervised option worth starting with.

Call: (415) 785-7995 Book: Schedule Your Medical Weight Loss Consultation

Related Services at PowerMD

• Semaglutide Medical Weight Loss Program: physician-supervised GLP-1 program
• Metformin: metabolic support and insulin sensitivity
• truSculpt iD Body Contouring: targeted fat reduction for areas that persist after weight loss
• truSculpt Flex Muscle Toning: muscle definition alongside weight reduction
• Non-Surgical Neck Lift: skin tightening for patients who experience skin laxity after significant weight loss
• Facial Volume Restoration: addressing the facial deflation that sometimes accompanies significant weight loss

Frequently Asked Questions

How fast does Semaglutide work?

Appetite changes are typically the first noticeable effect, often within the first one to two weeks. Visible weight loss for most patients begins in weeks four through eight, with the most significant monthly losses occurring between months two and five as the dose escalates to the therapeutic range.

How much weight can I realistically lose in 6 months on Semaglutide?

The STEP 1 trial showed a mean loss of approximately 14.9 percent of body weight at 68 weeks. Extrapolating to six months, and accounting for the dose escalation period, most physician-supervised patients lose 10 to 15 percent of starting body weight by month six. For a 200-pound starting weight, this is 20 to 30 pounds. Individual results vary significantly based on adherence, diet, exercise, and baseline metabolic health.

Why did I stop losing weight on Semaglutide?

A slowdown in weight loss rate at months three through five is common and physiologically expected. The most frequent contributing factors are dose approaching its ceiling, metabolic adaptation to lower caloric intake, and insufficient dietary protein or physical activity to preserve lean muscle mass. A follow-up appointment to assess dose optimization and dietary composition typically resolves this.

Is Ozempic the same as Wegovy?

Both contain Semaglutide as the active ingredient, but they are FDA-approved for different indications. Ozempic is approved for type 2 diabetes management at doses up to 2.0 mg. Wegovy is approved specifically for chronic weight management at the higher 2.4 mg dose. The mechanism is identical; the approved dosing and indication differ.

What happens to my skin after significant weight loss on Semaglutide?

Significant weight loss can sometimes result in skin laxity, particularly in the face, neck, abdomen, and arms. Many PowerMD patients who lose substantial weight on Semaglutide choose to follow their weight loss program with body contouring using truSculpt iD for remaining fat deposits, and laser skin tightening or facial volume restoration for areas where skin and facial volume have changed. Dr. Power plans for this transition as part of the overall weight loss program.

Can I combine Semaglutide with other treatments at PowerMD?

Yes. Many patients at PowerMD combine Semaglutide with aesthetic treatments that either support the process (body contouring) or address changes that occur alongside weight loss (facial rejuvenation, skin tightening). Dr. Power coordinates both the weight loss program and any aesthetic components as an integrated plan.